New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
February 5, 2014
06:54 EDTHALOHalozyme 7.69M share Secondary priced at $13.00
JPMorgan and Citigroup acted as joint book running managers for the offering.
News For HALO From The Last 14 Days
Check below for free stories on HALO the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
April 15, 2014
10:00 EDTHALOOn The Fly: Analyst Initiation Summary
Allscripts (MDRX) reinstated with an Outperform at Raymond James... Amber Road (AMBR) initiated with a Buy at Canaccord... Autonation (AN) coverage assumed with a Market Perform at Wells Fargo... BG Group (BRGYY) initiated with an Outperform at BMO Capital... Borderfree (BRDR) initiated with a Buy at Canaccord... Dean Foods (DF) initiated with a Buy at BB&T... Destination XL (DXLG) initiated with a Buy at Ascendiant... Group 1 Automotive (GPI) coverage assumed with a Market Perform at Wells Fargo... Halozyme (HALO) initiated with a Buy at Citigroup... MakeMyTrip (MMYT) initiated with a Neutral at Goldman... Penske Automotive (PAG) coverage assumed with a Market Perform at Wells Fargo... RPM (RPM) initiated with an Outperform at Wells Fargo... RSP Permian (RSPP) initiated with a Buy at KLR Group... Repligen (RGEN) initiated with a Buy at Jefferies... Spansion (CODE) initiated with a Buy at Sterne Agee... Statoil (STO) initiated with a Market Perform at BMO Capital... TPG Specialty Lending (TSLX) initiated with a Buy at BofA/Merrill... Versartis (VSAR) initiated with a Buy at Citigroup... WWE (WWE) initiated with a Buy at Needham... WebMD (WBMD) reinstated with a Strong Buy at Raymond James.
09:16 EDTHALOOn The Fly: Pre-market Movers
Subscribe for More Information
09:00 EDTHALOHalozyme rises 8.6%
Subscribe for More Information
05:42 EDTHALOHalozyme initiated with a Buy at Citigroup
Subscribe for More Information
April 9, 2014
08:09 EDTHALOHalozyme's PEGPH20 pancreatic cancer trial placed on hold
Subscribe for More Information
April 4, 2014
16:30 EDTHALOOn The Fly: Closing Wrap
Subscribe for More Information
12:09 EDTHALOOn The Fly: Midday Wrap
Subscribe for More Information
12:00 EDTHALOHalozyme falls 27.5%
Subscribe for More Information
10:00 EDTHALOHalozyme falls 24.4%
Subscribe for More Information
09:37 EDTHALOHalozyme defended after halt of Phase 2 trial enrollment at Piper Jaffray
Subscribe for More Information
09:13 EDTHALOOn The Fly: Pre-market Movers
HIGHER: Mylan (MYL), up 6.8% after report of desire to buy Swedish rival Meda, which confirmed it had been in talks with Mylan but rejected the company's takeover offer. Shares of Mylan were also upgraded to Buy this morning at Citigroup... Mercury Systems (MRCY), up 8.8% after Reuters said Boeing (BA) is considering a takeover bid of the supplier..Micron (MU), up 3% after reporting earnings and revenue that topped expectations... Align (ALGN), up 6% after winning patent case against ClearCorrect... GameStop (GME), up 2.8% following upgrade at BofA Merrill Lynch... Potbelly (PBPB), up 4.6% after upgrade at William Blair.... SYNNEX (SNX), up 18.5% after earnings report. LOWER: CarMax (KMX), down 3.3% after reporting earnings and revenue that fell below expectations... Halozyme (HALO), down 33% after announcing temporary halt of Phase 2 trial enrollment for PEGPH20... Ocean Power (OPTT), down 15% after 3.8M share Spot Secondary priced at $3.10.
09:07 EDTHALOHalozyme volatility elevated into temporary halt of Phase 2 trial enrollment
Halozyme volatility is expected to move after announces temporary halt of Phase 2 trial enrollment for PEGPH20. Overall option implied volatility of 89 is above its 26-week average of 72 according to Track Data, suggesting large price movement.
09:00 EDTHALOHalozyme falls 31%
Halozyme is down 31%, or $3.59, to $8.00
08:03 EDTHALOHalozyme announces temporary halt of Phase 2 trial enrollment for PEGPH20
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use